Get the Stockscreener App
44.72
1.22%
0.54
After Hours:
44.72
Edgewise Therapeutics Inc stock is traded at $44.72, with a volume of 1.04M.
It is up +1.22% in the last 24 hours and up +9.50% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$44.18
Open:
$43.67
24h Volume:
1.04M
Relative Volume:
0.75
Market Cap:
$4.86B
Revenue:
-
Net Income/Loss:
$-176.01M
P/E Ratio:
-26.92
EPS:
-1.661
Net Cash Flow:
$-148.97M
1W Performance:
+1.54%
1M Performance:
+9.50%
6M Performance:
+44.68%
1Y Performance:
+201.14%
1-Day Range:
$42.59
$45.44
1-Week Range:
$42.59
$46.59
52-Week Range:
$13.69
$48.40
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
44.72 | 4.70B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
EWTX Maintains Overweight Rating -- Price Target Raised to $60 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising SpendHas The Bull Case Changed? - simplywall.st
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Edgewise (EWTX) Results and Estimates: The Available Earnings Metric Delivers a Miss in the Available Record; Price Reaction: The Stock Ends Up 0.16% in Latest TradingConsensus Miss Rate - vinanet.vn
Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX) - Seeking Alpha
Edgewise Therapeutics (EWTX) corrects CFO option grant price - Stock Titan
Edgewise Therapeutics (EWTX) corrects CMO’s 65K option grant price - Stock Titan
Edgewise Therapeutics (EWTX) sets GC option price at $43.56 - Stock Titan
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56 - Stock Titan
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026 - Stock Titan
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd - MarketBeat
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP - MarketBeat
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich - Sahm
Edgewise Therapeutics (EWTX) Gains 2.29% to $44.17, Maintains Upside MomentumStock Surge Alerts - vinanet.vn
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock - Investing.com
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares - Investing.com
Edgewise Therapeutics CBO sells $223k in shares for tax obligations - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Australia
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock By Investing.com - Investing.com Canada
Joanne Donovan Sells 2,919 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock - MarketBeat
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares - MarketBeat
Edgewise Therapeutics President, CEO Sold Shares Worth Over $785K - TradingView
Edgewise Therapeutics (EWTX) GC nets RSU vesting, tax sales and new grants - Stock Titan
Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option - Stock Titan
Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes - Stock Titan
Edgewise Therapeutics (EWTX) CEO logs RSU vesting, sell-to-cover sales and 200,000 new options - Stock Titan
Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO - Stock Titan
RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares - Stock Titan
Paradigm BioCapital reports 9.5% stake in Edgewise Therapeutics (EWTX) common stock - Stock Titan
Edgewise Therapeutics (EWTX): Baker Bros. discloses 3.4% ownership in Schedule 13G/A - Stock Titan
Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC Expands Edgewise Therapeutics Inc (EWTX) Stake With 4.47 Million Share Purchase - GuruFocus
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by California State Teachers Retirement System - MarketBeat
Price-Driven Insight from (EWTX) for Rule-Based Strategy - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Edgewise Therapeutics Inc (EWTX) Stock News Today - TradingKey
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
FY2030 EPS Estimate for Edgewise Therapeutics Cut by Analyst - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Edgewise Therapeutics, Inc. Stock 12‑Month Price Target Raised to $50.46, Implies 12% Upside - TradingView
Edgewise ups R&D spending as pharma firm focuses on cardiovascular pipeline - BizWest
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
Aug 12 '26 |
Sale |
43.85 |
6,522 |
286,000 |
11,544 |
| Donovan Joanne M. | CMO |
Aug 13 '26 |
Sale |
43.41 |
2,919 |
126,704 |
8,625 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
12,812 |
0 |
37,367 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Sale |
43.73 |
5,901 |
258,042 |
31,466 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Option Exercise |
0.00 |
12,499 |
0 |
22,713 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Sale |
43.82 |
5,016 |
219,823 |
17,697 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
13,281 |
0 |
36,926 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Sale |
43.81 |
5,100 |
223,424 |
31,826 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Option Exercise |
0.00 |
39,844 |
0 |
70,459 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Sale |
43.68 |
17,971 |
785,042 |
52,488 |
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):